Quarterly ResultApr 28, 2026, 05:07 PM
NEO Q1 Revenue +11.1% to $186.7M; Net Loss Narrows to $17.1M
AI Summary
NEOGENOMICS INC reported a significant narrowing of its net loss in Q1 2026, reaching $(17.1) million compared to $(25.9) million in the prior year, alongside an 11.1% increase in net revenue to $186.7 million. The company also saw a substantial improvement in net cash used in operating activities, which decreased to $(8.1) million from $(25.3) million year-over-year. This quarter's results reflect ongoing efforts to improve financial performance following the acquisition of Pathline in April 2025 and the divestment of Trapelo Health in December 2025.
Key Highlights
- Net revenue increased 11.1% to $186.7 million for Q1 2026, up from $168.0 million YoY.
- Net loss narrowed to $(17.1) million in Q1 2026, an improvement from $(25.9) million YoY.
- Basic and diluted net loss per share improved to $(0.13) from $(0.20) YoY.
- Gross profit rose 10.4% to $80.9 million for Q1 2026, compared to $73.2 million YoY.
- Net cash used in operating activities significantly improved to $(8.1) million from $(25.3) million YoY.
- Cash and cash equivalents stood at $146.1 million as of March 31, 2026.
- Goodwill was adjusted by $(0.3) million in Q1 2026 related to the Pathline acquisition.
- Total stock-based compensation was $9.6 million, down from $10.8 million YoY.
Price Impact
More from NEO